Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria

INTRODUCTION: Patients with IgA nephropathy (IgAN) and persistent proteinuria are at risk of progression to kidney failure. Atacicept is a novel B-cell–targeted immunomodulator, shown to reduce immunoglobulin levels in patients with autoimmune diseases. METHODS: JANUS (NCT02808429) was a phase II st...

Descripción completa

Detalles Bibliográficos
Autores principales: Barratt, Jonathan, Tumlin, James, Suzuki, Yusuke, Kao, Amy, Aydemir, Aida, Pudota, Kishore, Jin, Hulin, Gühring, Hans, Appel, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366370/
https://www.ncbi.nlm.nih.gov/pubmed/35967104
http://dx.doi.org/10.1016/j.ekir.2022.05.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366370/
https://www.ncbi.nlm.nih.gov/pubmed/35967104
http://dx.doi.org/10.1016/j.ekir.2022.05.017

Ejemplares similares